Chemotherapy-induced peripheral neurotoxicity (CIPN) as a side effect of chemotherapy
negatively affects patients' quality of life and may lead to treatment disturbances. CIPN is
frequently recorded in patients treated with alkylating platinum-based drugs, antitubulins
including the taxanes and vinca alkaloids, and other drugs including suramin, thalidomide,
lenalidomide and the proteasome inhibitor bortezomib, representing one of the most severe and
potentially dose-limiting non-hematological toxic effects. Sufficient treatment options or
preventive measures are lacking.
There is evidence that physical activity strategies are able to address existing CIPN
symptoms and potentially increase quality of life in affected patients. CIPN symptoms
involves restrictions of sensory and sometimes motor modalities, for example, deficits in
plantar perception and dysfunction of postural control and one study in type II diabetes
patients also suggested that structured exercise might have a preventive potential with
regard to peripheral neuropathy incidence.
Based on these findings, we aim to investigate the preventive potential of a sensorimotor
intervention vs. machine-based resistance training vs. usual care (wait-list control group)
in a randomized controlled three-arm intervention trial among cancer patients undergoing
chemotherapy with high risk for CIPN. On the basis of power calculations, the goal is to
include 82 patients per intervention arm resulting in a total patients number to be enrolled
of n=246. CIPN symptoms will be assessed objectively via comprehensive clinical and
electrodiagnostic examinations (Total Neuropathy Scale; TNS-reduced) and subjectively via
questionnaires (EORTC QLQ-CIPN20 & FACT-GOG-Ntx, EORTC QLQ-C30). Additionally CIPN and the
effectiveness of the selected interventions will be objectively evaluated by spectral
analysis of Centre of Pressure (COP) variations. Further key secondary endpoints are:
physical performance, sleep quality and chemotherapy compliance.